Abilify Mycite 2021 U.S. PROMOTIONAL AUDIT REPORT

Published July 2022 • 22 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Abilify Mycite through reportable promotional activity in 2021 and how does this compare to its peer set in the Autism, Bipolar Disorder, Depression, Schizophrenia, and Tourette’s Syndrome markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Otsuka’s depth of coverage vary within key specialties (e.g., Nursing, Psychiatry, and Physician Assistant) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Abilify Mycite throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Abilify Mycite in 2021?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
• Over 2,570 paid interactions across 1,120 physicians made on behalf of Abilify Mycite were carefully examined to support our analysis. In addition, interaction data from 19 peer products (e.g. Abilify Maintena, Aplenzin, Aristada, Aristada Initio, Caplyta, Equetro, Fanapt, Invega Sustenna, Invega Trinza, Latuda, Lybalvi, Perseris, Rexulti, Secuado, Spravato, Trintellix, Viibryd, Vraylar, and Wellbutrin ) was leveraged to provide benchmarking and market insights.